Cochrane · systematic review · CD010832
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia
Sampford, JR, Sampson, S, Li, BG, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
10
No studies
18
Included studies
NR
No studies 18 · 64.3%Ungraded 0 · 0%Very low 10 · 35.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
FLUPHENAZINE (ORAL) compared to AMISULPRIDE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: Average endpoint score BPRS total score ‐ short term (up to 12 weeks) (high = poor) Brief Psychiatric Rating Scale (BPRS). Scale from: 0 to 108. FLUPHENAZINE (ORAL) vs AMISULPRIDE | no estimate extracted | 1 study · 57 participants | Very low Downgraded: risk of bias, imprecision |
Relapse (long term) ‐ not reported FLUPHENAZINE (ORAL) vs AMISULPRIDE | no estimate extracted | NR | No studies |
Clinically important change in life skills (long term) ‐ not measured FLUPHENAZINE (ORAL) vs AMISULPRIDE | no estimate extracted | NR | No studies |
Quality of life (long term) ‐ not measured FLUPHENAZINE (ORAL) vs AMISULPRIDE | no estimate extracted | NR | No studies |
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication FLUPHENAZINE (ORAL) vs AMISULPRIDE | RR 7.82 [1.07, 57.26] | 1 study · 36 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early ‐ any reason ‐ short term (up to 12 weeks) FLUPHENAZINE (ORAL) vs AMISULPRIDE | RR 1.19 [0.63, 2.28] | 2 studies · 98 participants | Very low Downgraded: risk of bias, imprecision |
Cost‐effectiveness (long term) ‐ not measured FLUPHENAZINE (ORAL) vs AMISULPRIDE | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) compared to RISPERIDONE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% FLUPHENAZINE (ORAL) vs RISPERIDONE | RR 0.67 [0.13, 3.35] | 1 study · 26 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse (long term) ‐ not reported FLUPHENAZINE (ORAL) vs RISPERIDONE | no estimate extracted | NR | No studies |
Clinically important change in life skills (long term) ‐ not reported FLUPHENAZINE (ORAL) vs RISPERIDONE | no estimate extracted | NR | No studies |
Quality of life (long term) ‐ not reported FLUPHENAZINE (ORAL) vs RISPERIDONE | no estimate extracted | NR | No studies |
Adverse effects: Extrapyramidal effects ‐ short/medium term (up to 12 weeks) ‐ not reported FLUPHENAZINE (ORAL) vs RISPERIDONE | no estimate extracted | NR | No studies |
Leaving the study early ‐ inefficacy short term (up to 12 weeks) FLUPHENAZINE (ORAL) vs RISPERIDONE | RR 1.08 [0.08, 15.46] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Cost‐effectiveness (long term) ‐ not reported FLUPHENAZINE (ORAL) vs RISPERIDONE | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) compared to QUETIAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% FLUPHENAZINE (ORAL) vs QUETIAPINE | RR 0.62 [0.12, 3.07] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Relapse (long term) FLUPHENAZINE (ORAL) vs QUETIAPINE | no estimate extracted | NR | No studies |
Clinically important change in life skills (long term) FLUPHENAZINE (ORAL) vs QUETIAPINE | no estimate extracted | NR | No studies |
Quality of life (long term) FLUPHENAZINE (ORAL) vs QUETIAPINE | no estimate extracted | NR | No studies |
Adverse effects: Extrapyramidal effects ‐ short/medium term (up to 12 weeks) FLUPHENAZINE (ORAL) vs QUETIAPINE | no estimate extracted | NR | No studies |
Leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) FLUPHENAZINE (ORAL) vs QUETIAPINE | RR 0.46 [0.05, 4.46] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Cost‐effectiveness (long term) FLUPHENAZINE (ORAL) vs QUETIAPINE | no estimate extracted | NR | No studies |
FLUPHENAZINE (ORAL) compared to OLANZAPINE for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of PANSS score < 40%, decreased rate of BPRS score < 40% FLUPHENAZINE (ORAL) vs OLANZAPINE | RR 1.33 [0.86, 2.07] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Relapse (long term) ‐ not reported FLUPHENAZINE (ORAL) vs OLANZAPINE | no estimate extracted | NR | No studies |
Clinically important change in life skills (long term) ‐ not reported FLUPHENAZINE (ORAL) vs OLANZAPINE | no estimate extracted | NR | No studies |
Quality of life (long term) ‐ not reported FLUPHENAZINE (ORAL) vs OLANZAPINE | no estimate extracted | NR | No studies |
Adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up to 12 weeks) FLUPHENAZINE (ORAL) vs OLANZAPINE | RR 3 [0.9, 10.01] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early: inefficacy ‐ short term (up to 12 weeks) FLUPHENAZINE (ORAL) vs OLANZAPINE | RR 3 [0.33, 27.23] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Cost‐effectiveness (long term) ‐ not reported FLUPHENAZINE (ORAL) vs OLANZAPINE | no estimate extracted | NR | No studies |